Scorpion spinout raises $177M to advance preclinical assets after 2 clinical programs sold to Pierre Fabre
After Eli Lilly snapped up Scorpion’s PI3Kα program earlier this year, the biotech is selling off its other two clinical assets and spinning out a new company to advance its three preclinical precision medicine candidates.
After Eli Lilly snapped up Scorpion’s PI3Kα program earlier this year, the biotech is selling off its other two clinical assets and spinning out a new company to advance its three preclinical precision medicine candidates.
